# Therapixel

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/therapixel

- Industry: Software
- Headquarters: Nice, France
- Website: www.therapixel.com
- Total disclosed funding: $18M
- Latest round: Series B (May 12, 2022)
- Investors on record: 11

## About

Therapixel SA is a French software company specializing in AI solutions for medical imaging, particularly enhancing breast cancer detection through its innovative product offerings.Therapixel SA, founded in 2013 in Nice, France, focuses on AI-driven medical imaging solutions designed to improve breast cancer screening. The company has successfully raised EUR 14.3 mn in a Series B funding round as of May 2022, involving investors such as Crédit Mutuel Equity and Cap Horn. The company was co-founded by Gael Varoquaux, Maxime Sermesant, and Pierre Fillard, with Matthieu Leclerc-Chalvet serving as the CEO. Therapixel has completed a total of 4 deals to date, with the most recent investment dating back to May 12, 2022. The company's current valuation stands at EUR 34.001 mn.Therapixel specializes in artificial intelligence solutions for medical imaging, particularly in the realm of breast cancer detection. Its flagship product, MammoScreen, utilizes advanced AI algorithms to assist radiologists in analyzing mammograms, enhancing accuracy in identifying potential abnormalities. This technology is designed to improve workflow in radiology departments, enabling healthcare providers to deliver timely care. MammoScreen is used in over 150 locations, including prominent institutions like Mayo Clinic, as part of a collaboration with Onsite Women’s Health.In 2022, Therapixel generated revenue of EUR 391,060.50, primarily through partnerships with healthcare providers who subscribe to its AI-driven solutions. MammoScreen is offered as a service that augments the imaging systems of medical institutions, with pricing structures tailored to the scale and specific needs of the clients.Following the Series B funding round concluded in May 2022, Therapixel plans to utilize the EUR 14.3 mn raised to accelerate the commercial deployment of its AI solutions for 2D and 3D mammography reading, particularly in the United States. The company aims to expand its market presence and enhance its product offerings, focusing on the integration of its technologies into healthcare systems to meet rising demands for advanced medical imaging solutions.

## Funding rounds

- Series B, May 12, 2022, $15M — Credit Mutuel Equity, Turenne Groupe, M Capital, Cap Horn, IT-Translation, Région Sud Investissement, Verve Capital
- Series A, Feb 6, 2019, $2.9M — Omnes Capital, SWEN Capital Partners, M Capital, Paca Investissement, IT-Translation, Créazur

## Investors

- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series A
- SWEN Capital Partners (https://capitalatlas.ai/funds/swen-capital-partners) — Series A
- M Capital (https://capitalatlas.ai/funds/m-capital) — Series A, Series B
- Paca Investissement — Series A
- IT-Translation (https://capitalatlas.ai/funds/it-translation) — Series A, Series B
- Créazur — Series A
- Credit Mutuel Equity (https://capitalatlas.ai/funds/credit-mutuel-equity) — Series B
- Turenne Groupe (https://capitalatlas.ai/funds/turenne-groupe) — Series B
- Cap Horn (https://capitalatlas.ai/funds/cap-horn) — Series B
- Région Sud Investissement (https://capitalatlas.ai/funds/region-sud-investissement) — Series B
- Verve Capital (https://capitalatlas.ai/funds/verve-capital) — Series B